On Tuesday, Edwards Lifesciences EW reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all product groups.
Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart?
Edwards Lifesciences Corporation (NYSE:EW ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mark Wilterding - Senior Vice President, Investor Relations Bernard Zovighian - Chief Executive Officer Scott Ullem - Corporate Vice President and Chief Financial Officer Daveen Chopra - Corporate Vice President, TMTT Larry Wood - Corporate Vice President and Group President of TAVR and SSH Conference Call Participants David Roman - Goldman Sachs Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Travis Steed - Bank of America Vijay Kumar - Evercore ISI Frederick Wise - Stifel Matthew Miksic - Barclays Matthew Taylor - Jefferies Joanne Wuensch - Citibank Mark Wilterding [Starts Abruptly] included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections.
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices.
Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Edwards Lifesciences Corporation EW shares are trading higher on Thursday.
Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.
Investors need to pay close attention to Edwards (EW) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.